Navigation Links
Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
Date:7/20/2009

NEW YORK, July 20 /PRNewswire/ -- Double Helix Consulting US, a division of London-based Double Helix Development group, today announced the appointment of Caryn Zieses to the position of Senior Consultant. Zieses joins a multidisciplinary team of highly experienced strategic pricing, reimbursement and market access consultants with extensive experience across the healthcare industry, which provides product commercialization services to firms in the pharmaceutical, biotechnology and medical device industries. DHC US provides services spanning the product lifecycle, including the following:

  • Product value message development and testing
  • Commercial assessment
  • Development program and clinical trial planning
  • Managed markets strategy
  • Pharmacoeconomic evaluation and health technology assessment
  • Payer and provider insight evaluation and influence planning
  • Pricing and reimbursement strategy, negotiation simulation, and training

Drew Baker, President of Double Helix Consulting US, commented, "Caryn complements our international market access, pricing and reimbursement capabilities through her vast experience in planning and implementing product development and launch strategies for the US market. Her intimate knowledge of managed care market structure, formulary management, contracting strategies, and marketing communications strengthens Double Helix's ability to meet our clients' commercial objectives in the increasingly cost-conscious and value-driven US market."

Chief Executive Officer of Double Helix Development Group, Dr. Wayne Phillips, added, "Double Helix Consulting offers a premier set of services to assist our clients in optimizing product commercialization by enhancing market access through a truly global team of professionals with deep experience from both the client and consulting sides. As an example, our growing emerging markets practice provides clients with the intelligence to implement successful strategies in the world's largest and most rapidly developing economies. Caryn's experience in product planning and launch strategy bolsters our expanding capabilities."

Zieses joins the Double Helix Consulting US team from the Pricing & Reimbursement consulting practice of IMS Health. She has worked closely with both large and small pharmaceutical and biotech clients to deliver global strategic recommendations that would inform decisions related to drug pricing, market access, clinical trial design, value messaging, payer attitudes, forecasting, and commercial assessments. Her expertise in US payer trends spans both public and private organizations and the policy changes they continually face. She has extensive experience in a diverse set of therapy areas, in particular those related to neurosciences, pulmonology, immunology and ophthalmology. She also has four years of previous client services experience in the Equity Research division of Lehman Brothers. Caryn holds an MBA from the Kellogg School of Management, an MEM from Northwestern University, and a BSE in Chemical Engineering from the University of Pennsylvania.

http://www.doublehelixdevelopment.com

(Photo: http://www.newscom.com/cgi-bin/prnh/20090720/NY49139 )

(Logo: http://www.newscom.com/cgi-bin/prnh/20090330/NY91277LOGO )


'/>"/>
SOURCE Double Helix Consulting US
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products
2. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
3. Nanoparticles double their chances of getting into sticky situations
4. Carbon nanotube avalanche process nearly doubles current
5. SleepQuest Compliance Again Doubles Industry Average
6. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
7. Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1
8. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
9. Method sorts out double-walled carbon nanotube problem
10. Premier Research Achieves Double-Digit Growth in Functional Sourcing for the Third Straight Year
11. US Neuropathic Pain Market Value Doubles to $5 Billion by 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
Breaking Biology News(10 mins):